A Fatal Case of Rhizopus azygosporus Pneumonia Following COVID-19
Anubhav Kanwar, Alex Jordan, Scott Olewiler, Kurt Wehberg, Michael Cortés, Brendan R. Jackson
Abstract
pneumonia in a 56-year-old man hospitalized for COVID-19 who had received methylprednisolone and tocilizumab. Although COVID-associated pulmonary aspergillosis has been widely documented, mucormycosis has been rarely reported. In this patient, receipt of two commonly used immunosuppressants likely contributed to mucormycosis risk, suggesting the need for vigilance in hospitalized patients with COVID-19.
Topics & Concepts
MucormycosisMedicinePneumoniaCoronavirus disease 2019 (COVID-19)ZygomycosisMethylprednisoloneTocilizumabAspergillosisIntensive care medicineAmphotericin BPediatricsInternal medicineImmunologyDermatologyInfectious disease (medical specialty)SurgeryDiseaseAntifungalAntifungal resistance and susceptibilityFungal Infections and StudiesPneumocystis jirovecii pneumonia detection and treatment